^
Association details:
| Biomarker: | SERPINB3 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy
Published date:
09/08/2022
Excerpt:
In this study, we analyzed the potential genomic indicators contributing to ICB therapy response. The results showed that high tumor mutation burden (TMB) failed to predict response in anti-PD1 treated melanoma. SERPINB3 was the most significant response-related gene in melanoma...
DOI:
10.3390/cells11182802
